Idorsia reacquires aprocitentan rights from Janssen for $343m

Amid financial issues, Idorsia is hoping the resistant hypertension drug would boost the company’s profits.

Sep 7, 2023 - 20:00

Idorsia reacquires aprocitentan rights from Janssen for $343m

Amid financial issues, Idorsia is hoping the resistant hypertension drug would boost the company’s profits.

Read the original article

Tags:

Previous Article

AstraZeneca mulls risk strategy for Ultomiris following FDA response letter

Revvity introduces advanced preclinical imaging tech for scientists to make brea...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Do diet drugs pull their weight?

Do diet drugs pull their weight?

Sep 13, 2023

STAT+: Pharmalittle: Medicare looks to improve Alzheimer’s care but sidesteps drug prices; CVS to cut 5,000 jobs

STAT+: Pharmalittle: Medicare looks to improve Alzheime...

Aug 1, 2023

As midwife-assisted home births rise, so too do high-risk births outside hospitals

As midwife-assisted home births rise, so too do high-ri...

Feb 23, 2024